

William R Macon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9186765/publications.pdf>

Version: 2024-02-01

77
papers

2,584
citations

361296
20
h-index

189801
50
g-index

79
all docs

79
docs citations

79
times ranked

3405
citing authors

#	ARTICLE	IF	CITATIONS
1	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	0.6	401
2	Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the <sc>US</sc>: A longitudinal analysis of the <sc>N</sc>ational <sc>C</sc>ancer <sc>D</sc>ata <sc>B</sc>ase from 1998 to 2011. <i>American Journal of Hematology</i> , 2015, 90, 790-795.	2.0	221
3	Hepatosplenic ÉÏ T-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2001, 25, 285-296.	2.1	214
4	Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. <i>Modern Pathology</i> , 2008, 21, 455-463.	2.9	195
5	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4191-4198.	0.8	184
6	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	2.0	180
7	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. <i>Blood</i> , 2018, 131, 2060-2064.	0.6	167
8	Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?. <i>Blood</i> , 2005, 106, 1501-1502.	0.6	161
9	Hepatosplenic and Subcutaneous Panniculitis-Like Î³Î´ T Cell Lymphomas Are Derived from Different Î³Î´ Subsets of Î³Î´ T Lymphocytes. <i>Journal of Molecular Diagnostics</i> , 2000, 2, 11-19.	1.2	104
10	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood</i> , 2015, 126, 328-335.	0.6	92
11	Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1620-1626.	0.8	70
12	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	0.9	57
13	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.	1.7	52
14	Clinical heterogeneity of diffuse large B cell lymphoma following failure of frontâ€line immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	1.2	49
15	Incidence ofTCRandTCL1Gene Translocations and Isochromosome 7q in Peripheral T-Cell Lymphomas Using Fluorescence In Situ Hybridization. <i>American Journal of Clinical Pathology</i> , 2008, 130, 178-185.	0.4	45
16	Personalized risk prediction for eventâ€free survival at 24 months in patients with diffuse large Bâ€cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
17	Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. <i>Human Pathology</i> , 2017, 64, 19-27.	1.1	41
18	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.	3.3	28

#	ARTICLE	IF	CITATIONS
19	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 448-453.	2.0	26
20	Follicular Dendritic Cell Sarcoma With Indolent T-Lymphoblastic Proliferation Is Associated With Paraneoplastic Autoimmune Multiorgan Syndrome. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1647-1652.	2.1	23
21	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018, 8, 63.	2.8	22
22	Desmoplastic Infantile Ganglioglioma: A MAPK Pathway-Driven and Microglia/Macrophage-Rich Neuroepithelial Tumor. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 1011-1021.	0.9	21
23	Peripheral T-Cell Lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 829-842.	0.9	16
24	Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 427-433.	1.2	15
25	Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 786-793.	2.0	15
26	Elucidating a false-negative MYC break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with IGH/MYC and IGH/BCL2 rearrangements. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004077.	0.5	14
27	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. <i>Leukemia and Lymphoma</i> , 2020, 61, 3351-3359.	0.6	14
28	Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. <i>Hematological Oncology</i> , 2018, 36, 749-756.	0.8	13
29	Neurolymphomatosis: A report of 2 cases representing opposite ends of the clinical spectrum. <i>Muscle and Nerve</i> , 2015, 52, 449-454.	1.0	9
30	Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. <i>Oncologist</i> , 2020, 25, 689-695.	1.9	7
31	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. <i>HemaSphere</i> , 2021, 5, e640.	1.2	7
32	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2683-2683.	0.6	6
33	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.	1.2	5
34	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.	0.6	5
35	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3035-3035.	0.6	5
36	Hypomagnesemia is associated with an increased risk of early clinical failure in patients with Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2274-2276.	0.6	4

#	ARTICLE	IF	CITATIONS
37	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2021, 149, 535-545.	2.3	4
38	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021, 11, 133.	2.8	4
39	Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD). <i>Blood</i> , 2018, 132, 456-456.	0.6	4
40	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.	0.6	4
41	Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. <i>Blood</i> , 2013, 122, 4179-4179.	0.6	4
42	What, how, and when for the WHO: will the clock be turned back for the next hematolymphoid tumor classification?. <i>Journal of Hematopathology</i> , 2021, 14, 185-186.	0.2	3
43	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. <i>Blood Cancer Journal</i> , 2021, 11, 160.	2.8	3
44	Syk Tyrosine Kinase Is Overexpressed in the Majority of Peripheral T- and NK-Cell Lymphomas, and Represents a Potential Therapeutic Target.. <i>Blood</i> , 2007, 110, 690-690.	0.6	3
45	Bone involvement on PET/CT predicts event-free survival in follicular lymphoma Grade 3B. <i>British Journal of Haematology</i> , 2020, 191, e41-e43.	1.2	2
46	Twenty years later: has cell of origin testing in diffuse large B cell lymphoma run its course?. <i>Journal of Hematopathology</i> , 2020, 13, 1-3.	0.2	2
47	Cutaneous ALK-positive histiocytosis. <i>Journal of Hematopathology</i> , 2021, 14, 89-91.	0.2	2
48	An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation. <i>Blood</i> , 2018, 132, 2247-2247.	0.6	2
49	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	0.6	2
50	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. <i>Blood</i> , 2013, 122, 362-362.	0.6	2
51	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". <i>Blood</i> , 2016, 128, 1750-1750.	0.6	2
52	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. <i>Blood</i> , 2016, 128, 3033-3033.	0.6	2
53	Academic boycotts of Russian science: where does the Journal of Hematopathology stand?. <i>Journal of Hematopathology</i> , 2022, 15, 49-49.	0.2	2
54	Computational histopathology and deep transfer learning: characterizing the molecular basis of tumor morphology. <i>Journal of Hematopathology</i> , 2020, 13, 203-204.	0.2	1

#	ARTICLE	IF	CITATIONS
55	COVID-19 and remembering Professor Dennis H. Wright. <i>Journal of Hematopathology</i> , 2020, 13, 77-78.	0.2	1
56	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. <i>Blood</i> , 2018, 132, 4204-4204.	0.6	1
57	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018, 132, 2962-2962.	0.6	1
58	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1104-1104.	0.6	1
59	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). <i>Blood</i> , 2016, 128, 155-155.	0.6	1
60	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , 2016, 128, 5299-5299.	0.6	1
61	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	2.8	1
62	SOLAHP: a fledgling organization rapidly taking flight. <i>Journal of Hematopathology</i> , 2019, 12, 107-107.	0.2	0
63	Advancing diagnostic hematopathology: pigeons or pixels?. <i>Journal of Hematopathology</i> , 2019, 12, 49-50.	0.2	0
64	Keeping tabs on the mabs: a hematopathologist's dilemma. <i>Journal of Hematopathology</i> , 2019, 12, 1-2.	0.2	0
65	Assessing for disease: recurrent mycosis fungoides or cutaneous granulomatous drug eruption after mogamulizumab therapy. <i>Journal of Hematopathology</i> , 2020, 13, 287-288.	0.2	0
66	A radiology survey and sub-sub-specialization in hematopathology. <i>Journal of Hematopathology</i> , 2021, 14, 1-2.	0.2	0
67	SARS-CoV-2/COVID-19 pandemic produces a new paradigm for international hematopathology meetings. <i>Journal of Hematopathology</i> , 2021, 14, 95-95.	0.2	0
68	MYC Translocations Are Associated with Poor Overall Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras. <i>Blood</i> , 2009, 114, 443-443.	0.6	0
69	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. <i>Blood</i> , 2016, 128, 3036-3036.	0.6	0
70	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study. <i>Blood</i> , 2016, 128, 5322-5322.	0.6	0
71	Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018. <i>Blood</i> , 2018, 132, 574-574.	0.6	0
72	Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. <i>Blood</i> , 2018, 132, 2979-2979.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019, 134, 1480-1480.	0.6	0
74	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021, 138, 2508-2508.	0.6	0
75	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
76	Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
77	Histiocyte-rich pseudotumor "a post-chemotherapy radiologic dilemma. <i>Journal of Hematopathology</i> , 2022, 15, 45.	0.2	0